Tarsus Pharmaceuticals, Inc.
TARS
$46.47
$2.906.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -23.11M | -23.42M | -33.29M | -35.73M | -41.90M |
| Total Depreciation and Amortization | 432.00K | 284.00K | 239.00K | 270.00K | 347.00K |
| Total Amortization of Deferred Charges | 138.00K | 129.00K | 101.00K | 114.00K | 111.00K |
| Total Other Non-Cash Items | 6.09M | 6.45M | 8.29M | 6.15M | 4.92M |
| Change in Net Operating Assets | -5.73M | 7.91M | 10.25M | -8.59M | -2.81M |
| Cash from Operations | -22.18M | -8.65M | -14.40M | -37.79M | -39.34M |
| Capital Expenditure | -72.00K | -282.00K | -1.04M | -174.00K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -59.50M | 3.41M | -39.49M | -102.05M | 17.85M |
| Cash from Investing | -59.57M | 3.13M | -40.53M | -102.22M | 17.85M |
| Total Debt Issued | 0.00 | 0.00 | 75.00M | -- | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.93M | 678.00K | -- | 108.77M | 19.76M |
| Repurchase of Common Stock | -- | -- | -6.69M | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -39.00K | -26.00M | -- | -- |
| Cash from Financing | 2.93M | 639.00K | 42.32M | 108.77M | 19.76M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -78.83M | -4.89M | -12.61M | -31.24M | -1.73M |
